{"product_id":"bhc-bcg-matrix","title":"(BHC) Bausch Health Companies Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bausch Health Companies Inc. BCG Matrix is a company-specific strategy tool used to assess products or business units across the Stars, Cash Cows, Question Marks, and Dogs framework. The page already includes a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLumify, U.S. OTC eye redness brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLumify, launched in 2018, sits in the large U.S. OTC eye-redness market, where demand keeps expanding with everyday use. Bausch + Lomb’s wide retail reach and strong brand recall help drive repeat buys, while premium pricing supports margins. That mix of growth, scale, and sticky demand fits a Star profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolta Medical, global aesthetics devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolta Medical sells energy-based aesthetics systems such as Thermage, Fraxel, and Clear + Brilliant across North America, Europe, and Asia-Pacific. The medical aesthetics devices market kept growing in 2025, led by rising elective skin-treatment demand and repeat use. With 3 flagship brands and stronger growth than Bausch Health's mature units, Solta fits the Star quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb surgical ophthalmology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb's surgical ophthalmology platform sells cataract and other eye-surgery products into a specialized market with recurring placements and sticky surgeon relationships. Global demand stays strong as populations age; the WHO said 1.1 billion people were age 60+ in 2024, a base that keeps lifting procedure volumes. Its established share in this growing niche fits a Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBausch + Lomb premium contact lenses, ULTRA and INFUSE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb’s ULTRA and INFUSE fit a Star in Bausch Health Companies Inc.’s BCG matrix: premium contact lens demand keeps shifting toward comfort, and Bausch + Lomb has broad global reach, strong brand depth, and wide distribution in eye care. That mix supports growth and share gains in a higher-value category.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium comfort lenses keep trading up\u003c\/li\u003e\n\u003cli\u003eGlobal eye-care footprint supports scale\u003c\/li\u003e\n\u003cli\u003eBrand depth helps repeat buying\u003c\/li\u003e\n\u003cli\u003eDistribution widens market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMiebo, dry-eye prescription drop\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMiebo, approved in the U.S. in May 2023, is a newer drug in a dry-eye market that affects about 38 million U.S. adults, so the runway is still long. Dry-eye diagnosis and treatment are rising, which supports growth. Early launches need heavy doctor promotion, payer access, and patient education, but that is normal for a new category entrant.\u003c\/p\u003e\n\u003cp\u003eFor Bausch Health Companies Inc., Miebo fits the Star box: high-growth market, early uptake, and room to scale if access improves. The key watchpoint is whether Bausch + Lomb can turn launch spend into durable prescription growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. approval: May 2023\u003c\/li\u003e\n\u003cli\u003eMarket size: about 38 million adults\u003c\/li\u003e\n\u003cli\u003eStage: early commercialization\u003c\/li\u003e\n\u003cli\u003eBCG view: Star potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch Health’s Stars Shine in Expanding Eye-Care and Aesthetics Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch Health Companies Inc.’s Stars are Lumify, Solta Medical, surgical ophthalmology, ULTRA and INFUSE, and Miebo. They sit in growing markets: dry eye affects about 38 million U.S. adults, the world had 1.1 billion people aged 60+ in 2024, and 2025 aesthetics and eye-care demand kept rising. Strong brands, broad distribution, and repeat use support share gains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiebo\u003c\/td\u003e\n\u003ctd\u003eDry-eye growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolta Medical\u003c\/td\u003e\n\u003ctd\u003e2025 demand rise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLumify\u003c\/td\u003e\n\u003ctd\u003eOTC scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBausch Health’s BCG Matrix maps its portfolio to spot Stars, Cash Cows, Questions, and Dogs for invest, hold, or divest calls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBausch Health BCG Matrix: one-page quadrant view that quickly spots pain points and growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Bausch Health Companies Inc., helping verify key claims quickly and strengthening decision-making confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXifaxan, U.S. GI franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXifaxan is Bausch Health Companies Inc.'s flagship GI brand, and 2024 net sales were about $1.1 billion. Demand is long-standing and the U.S. GI market is mature, so growth is limited. That mix of high cash generation and low growth is classic Cash Cow territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreserVision AREDS 2, eye vitamin leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePreserVision AREDS 2 is a mature, repeat-buy OTC eye vitamin brand in age-related eye health, so it fits the Cash Cow box well. Bausch Health Companies Inc. does not break out PreserVision revenue separately in recent public reporting, but the brand’s long shelf life, strong recognition, and pharmacy placement support steady 2025 cash flow. With low innovation needs and a stable, aging customer base, it keeps generating cash rather than consuming it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJublia, toenail fungus treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJublia is Bausch Health Companies Inc.'s established toenail fungus brand, approved in 2014 and still selling through long prescription history and brand recall. In Bausch Health Companies Inc.'s 2025 filings, the dermatology segment remained a steady contributor even as growth slowed versus newer launches. Its niche market and mature demand fit a Cash Cow profile: low growth, durable sales, and reliable cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLotemax and Alrex, ophthalmic steroid brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLotemax and Alrex are long-running prescription ophthalmic steroids with clear use cases, so they fit Bausch Health Companies Inc.'s Cash Cow bucket. Their market is mature, not fast-growing, and Bausch Health can keep serving repeat demand with relatively low added investment. Public filings do not break out brand-level 2025\/2026 revenue, but the steady eye-care cash flow pattern is exactly what a Cash Cow looks like.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished, narrow prescription use\u003c\/li\u003e\n\u003cli\u003eLow growth, stable demand\u003c\/li\u003e\n\u003cli\u003eRecurring revenue, modest reinvestment\u003c\/li\u003e\n\u003cli\u003eStrong Cash Cow profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotrue, mature eye-care consumer line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotrue is a mature lens-care and eye-health line sold through retail, so it sits in Bausch Health Companies Inc.’s Cash Cow bucket: high share, low growth, and steady cash generation. Its strength is Bausch + Lomb’s broad distribution scale, which helps keep shelf presence and repeat purchases stable. Growth is not fast, but the franchise still supports dependable volume and margin mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail lens care and eye-health brand\u003c\/li\u003e\n\u003cli\u003eMature, steady demand profile\u003c\/li\u003e\n\u003cli\u003eBacked by Bausch + Lomb scale\u003c\/li\u003e\n\u003cli\u003eFits low-growth, high-share Cash Cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch’s Cash Cows: Xifaxan Leads the Pack\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXifaxan led Bausch Health Companies Inc. cash cows, with 2024 net sales near $1.1 billion, while PreserVision, Jublia, Lotemax\/Alrex, and Biotrue stayed in mature, repeat-use niches. These brands share low growth, strong recognition, and limited reinvestment needs, so they keep throwing off cash instead of burning it. That is the core Cash Cow profile.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXifaxan\u003c\/td\u003e\n\u003ctd\u003e$1.1B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreserVision\u003c\/td\u003e\n\u003ctd\u003eStable OTC demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJublia\u003c\/td\u003e\n\u003ctd\u003eMature Rx niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBausch Health Companies Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the actual Bausch Health Companies Inc. BCG Matrix report you’ll receive after purchase. The document is identical to the final file—no demo pages, no placeholders, and no hidden changes. It’s ready for immediate download, review, or use in your strategic analysis. Buy once and get the complete, professional version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelistor, opioid-induced constipation brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRelistor remains a Dog in Bausch Health Companies Inc.’s BCG Matrix because it serves a narrow opioid-induced constipation niche and has not scaled into a broad-market brand. Sales rely on a specialized prescriber base, while competition from other constipation therapies keeps growth capped. That limited reach makes Relistor less attractive than Bausch Health Companies Inc.’s larger franchise assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSiliq, psoriasis biologic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSiliq, a psoriasis biologic from Bausch Health Companies Inc., stays a niche brand in a crowded market with many larger rivals. It has not reached scale, and uptake has stayed well below leading dermatology biologics.\u003c\/p\u003e\n\u003cp\u003eThat makes it a classic low-share, low-growth asset in the BCG matrix. In a category where top brands dominate prescriptions and payer access, Siliq has remained a small player.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDuobrii, topical psoriasis therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDuobrii sits in a crowded topical psoriasis market, where generics, steroids, and nonsteroid creams keep pricing and share tight. Bausch Health Companies Inc. has not shown Duobrii as a high-scale growth driver, and its commercial push has not converted into meaningful market depth. With limited growth and no clear path to large share, it fits the Dog quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBryhali, topical corticosteroid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBryhali 0.01% is a topical corticosteroid for plaque psoriasis, a narrow dermatology niche where low-cost generics and newer biologics keep pricing and volume pressure high. With limited label breadth and no clear 2025 momentum, it fits a Dog in Bausch Health Companies Inc.'s BCG mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.01% topical steroid\u003c\/li\u003e\n\u003cli\u003eSmall, niche psoriasis use\u003c\/li\u003e\n\u003cli\u003eCompetitive, mature category\u003c\/li\u003e\n\u003cli\u003eLimited 2025 growth signal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy generics and dental products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy generics and dental products fit Dogs because they are mature, fragmented lines with weak differentiation and low pricing power. In Bausch Health Companies Inc., these businesses usually earn modest returns while capital stays tied up in inventory, plants, and compliance. That makes cash generation limited versus the capital base.\u003c\/p\u003e\n\u003cp\u003eGeneric drug prices keep falling as competition rises, and dental products face the same squeeze from commoditized demand. For Bausch Health Companies Inc., that means these lines are better viewed as cash harvest assets than growth engines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow pricing power\u003c\/li\u003e\n\u003cli\u003eFragmented, mature markets\u003c\/li\u003e\n\u003cli\u003eModest return on capital\u003c\/li\u003e\n\u003cli\u003eBest fit: Dog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch Health’s Dogs: Harvest, Don’t Grow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Bausch Health Companies Inc.’s BCG mix are Relistor, Siliq, Duobrii, Bryhali 0.01%, and mature generics and dental lines. They sit in slow or crowded niches, with weak share and limited 2025 growth. That keeps pricing power low and cash returns modest. Bausch Health Companies Inc. should treat them as harvest assets, not growth engines.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrulance, U.S. constipation and IBS-C brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrulance, approved by the U.S. FDA in 2017, sits in a growing GI market, but it still trails better-known rivals like Linzess, so Bausch Health Companies Inc. has not built dominant share. That fits a Question Mark: the category can expand, but Trulance needs much more scale to turn growth into a leadership position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXiidra, dry-eye prescription therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXiidra sits in a large dry-eye market that keeps growing; the U.S. has about 16 million diagnosed dry-eye patients, and prescription demand is still expanding. But competition from Restasis, Cequa, Miebo, and OTC drops keeps share from becoming clearly dominant. That means Xiidra has upside, yet it still needs steady marketing and access spend to defend and grow prescriptions, which fits Question Mark territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyzulta, glaucoma therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVyzulta competes in a chronic glaucoma market serving about 80 million people worldwide in 2020, with demand set to reach 111.8 million by 2040. \u003c\/p\u003e\n\u003cp\u003eIt is a once-daily prostaglandin option, but its share still trails top leaders like latanoprost, so Bausch Health Companies Inc. has not turned it into a category winner. \u003c\/p\u003e\n\u003cp\u003eThat keeps Vyzulta in the Question Mark box: the market is large and sticky, but growth depends on stronger adoption and better sales execution. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eArazlo, acne topical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArazlo, Bausch Health Companies Inc.’s 0.045% tazarotene acne lotion, sits in a growing prescription acne market, but it is still early in its life cycle and must win physician habit one script at a time. Competitive pressure is heavy from entrenched topical retinoids and combination therapies, so the brand has not yet earned a clear share lead. That keeps Arazlo in the Question Mark box.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.045% tazarotene strength\u003c\/li\u003e\n\u003cli\u003eNewer brand, still gaining adoption\u003c\/li\u003e\n\u003cli\u003eHigh competition keeps risk elevated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCabtreo, acne combination gel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCabtreo, launched in 2023, fits a Question Mark because it entered a large, still-growing acne market but has not yet built meaningful share. Early products like this usually need heavy promotion, payer access work, and formulary wins before sales scale. Its value depends on how fast Bausch Health can turn first use into repeat prescriptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 launch; share still building.\u003c\/li\u003e\n\u003cli\u003eNeeds strong promotion and access.\u003c\/li\u003e\n\u003cli\u003eUpside depends on Rx momentum.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch Health’s Brands Have Upside, But Share Gains Are the Key\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch Health Companies Inc.’s Question Marks have clear upside, but they still need share gains. Trulance, Xiidra, Vyzulta, Arazlo, and Cabtreo each sit in large or growing markets, yet none has dominant scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrulance\u003c\/td\u003e\n\u003ctd\u003eGI growth, weak share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXiidra\u003c\/td\u003e\n\u003ctd\u003e16M U.S. dry-eye patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVyzulta\u003c\/td\u003e\n\u003ctd\u003e111.8M glaucoma by 2040\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCabtreo\u003c\/td\u003e\n\u003ctd\u003e2023 launch, early share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234070896905,"sku":"bhc-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bhc-bcg-matrix.webp?v=1785712953","url":"https:\/\/dcfanalyst.com\/products\/bhc-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}